Pfizer Submits Favorable Initial Data To The FDA On Kids’ COVID-19 Vaccine Trial

An older kid gets immunized in Michigan. Pfizer and BioNTech say they will send an official request for emergency situation use permission of the vaccine in kids as young as 5 in the coming weeks.

Emily Elconin/Bloomberg via Getty Images

conceal caption

toggle caption

Emily Elconin/Bloomberg via Getty Images

An older child gets immunized in Michigan. Pfizer and BioNTech state they will submit an official ask for emergency use permission of the vaccine in kids as young as 5 in the coming weeks.

Emily Elconin/Bloomberg through Getty Images

Pfizer and BioNTech are another action better to seeking permission for young children to receive the COVID-19 coronavirus vaccine, sending data to the Food and Drug Administration that reveals a “robust” antibody action and “favorable” safety results in kids ages 5 to 11 who got the two-dose regimen in scientific trials. News of the data submission comes a week after Pfizer revealed promising outcomes from the trials, which have been closely watched by moms and dads excited to safeguard their children from the coronavirus. Kids got two vaccine dosages of 10 micrograms– especially smaller than the set of 30-microgram doses used in an earlier effective trial for individuals 16 to 25 years old.

Pfizer and BioNTech are another step more detailed to seeking authorization for young kids to receive the COVID-19 coronavirus vaccine, submitting data to the Food and Drug Administration that shows a “robust” antibody action and “favorable” security results in kids ages 5 to 11 who received the two-dose regimen in medical trials. News of the data submission comes a week after Pfizer revealed promising results from the trials, which have been carefully watched by moms and dads excited to safeguard their children from the coronavirus. Kids received 2 vaccine doses of 10 micrograms– especially smaller than the set of 30-microgram doses utilized in an earlier successful trial for individuals 16 to 25 years old.

The outcomes of the two trials are comparable, the business said as they announced the data submission to the FDA. In a different medical trial for kids more youthful than 5, participants are receiving 3-microgram doses of the vaccine. The pharmaceutical business anticipate to have outcomes of trials for kids from 6 months up to 2 years of ages and from ages 2 to 5 “as soon as the fourth quarter of this year.”

Leave a Reply

Your email address will not be published. Required fields are marked *